The virus making headlines is Oropouche, a tropical illness that surged dramatically starting in late 2023. Over 11,600 confirmed cases were reported across the Americas in 2024, including two deaths, with the virus appearing in countries where it had never been detected before. While most people recover quickly, the rapid spread into new regions and concerning risks during pregnancy have put global health authorities on alert.
What Oropouche Virus Actually Is
Oropouche virus was first identified in 1955 in Trinidad and Tobago, so it isn’t technically new. What is new is its explosive spread. The virus had circulated quietly in parts of South America for decades, but beginning in December 2023, case counts spiked and the virus turned up in places it had never reached before. By November 2024, ten countries and one territory in the Americas had confirmed cases: Brazil (the epicenter with over 9,500 cases), Peru, Cuba, Bolivia, Colombia, and others, plus 94 imported cases in the United States and two in Canada.
The virus belongs to the same broad family as other insect-borne viruses, and it causes a febrile illness commonly called Oropouche fever.
How It Spreads
Despite being called a “mosquito virus” in many headlines, the primary carrier is actually a tiny insect called a biting midge. These are much smaller than mosquitoes, sometimes called “no-see-ums,” and the species most responsible is Culicoides paraensis. Several mosquito species can also carry and transmit the virus, which is why it gets lumped in with mosquito-borne diseases.
The transmission cycle works in two stages. In forested areas, the virus circulates between mosquitoes and wild animals like sloths, primates, and birds. When an infected person travels from a forested area to a city, urban-dwelling midges and mosquitoes bite them, pick up the virus, and spread it to other people. This forest-to-city pipeline is what drives outbreaks. Biting midges are the main spreaders in urban settings, though a common house mosquito species has also been implicated.
Midges breed in a wide variety of wet environments: ponds, swamps, decaying organic matter, rotting fruit, and even unusual water sources with harsh chemical conditions. They can be active throughout the day, from morning through sunset, which makes avoidance harder than with mosquitoes that bite mainly at dawn and dusk.
Symptoms and Timeline
Oropouche fever typically begins within two weeks of being bitten. The hallmark symptoms are high fever, severe headache, muscle aches, stiff joints, chills, nausea, vomiting, and sensitivity to light. The illness looks almost identical to dengue, Zika, and chikungunya, which makes it difficult to tell apart from those infections based on symptoms alone. Most people recover within a few days to a week.
A small percentage of patients develop more serious complications. Neurological involvement, though rare, has been documented. The two confirmed deaths in 2024, both in Brazil, underscored that severe outcomes are possible even if uncommon.
Pregnancy Risks
The most alarming finding from the 2024 surge involves pregnancy. Based on a small but growing number of cases, Oropouche virus can cross from a pregnant person to the fetus during pregnancy or around the time of birth. This has been associated with stillbirth and birth defects, including microcephaly, a condition where a baby’s head is significantly smaller than expected. These parallels to Zika virus are part of what elevated Oropouche from a regional concern to an international one.
The CDC advises pregnant travelers to discuss their plans with a healthcare provider before visiting affected areas. There is also preliminary concern about possible sexual transmission of the virus. As a precaution, the CDC suggests that travelers and their partners consider using condoms or abstaining for six weeks after returning from an affected region.
Diagnosis Is Tricky
Because Oropouche symptoms overlap so heavily with dengue, Zika, and other tropical fevers, a blood test is the only way to confirm it. The primary diagnostic tool is a molecular test called RT-qPCR, which detects the virus’s genetic material during the acute phase of illness. No rapid point-of-care test exists yet, so samples need to go to a lab. Antibody testing can confirm infection after the first week of symptoms but requires specialized laboratories to distinguish Oropouche from closely related viruses.
This diagnostic gap is a real problem. In regions where multiple tropical viruses circulate simultaneously, many Oropouche cases are likely being misdiagnosed as dengue, meaning the true case count could be significantly higher than reported.
No Vaccine, No Specific Treatment
There is currently no vaccine for Oropouche and no antiviral drug that targets it. Treatment is purely supportive: rest, fluids, and fever reducers. Most people feel better within a week without medical intervention. For the small number who develop severe symptoms, hospital care focuses on managing complications as they arise.
How to Protect Yourself
Prevention comes down to avoiding bites. The CDC currently rates Oropouche in the Americas at Level 1, its lowest alert tier, meaning travelers should practice usual precautions. In practical terms, that means using EPA-registered insect repellent, wearing long sleeves and pants in affected areas, and staying in places with screens or air conditioning. Standard mosquito netting may not block midges because of their tiny size, so repellent-treated netting is a better option.
If you travel to an affected area, the CDC recommends continuing to prevent bites for three weeks after returning home. This isn’t to protect you; it’s to prevent a local midge or mosquito from biting you and potentially establishing transmission in a new area. If you develop fever, headache, or muscle aches within two weeks of traveling to Brazil, Peru, Cuba, Bolivia, or other affected countries, let your doctor know where you’ve been so they can test for the right infections.
Oropouche is now a nationally notifiable condition in the United States, meaning confirmed cases are tracked through the national arbovirus surveillance system. Health agencies across the Americas are actively monitoring the virus’s spread, but the combination of a hard-to-avoid insect vector, easy misdiagnosis, and no vaccine means this is a virus likely to keep expanding before it’s contained.